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The bacterium Staphylococcus aureus is a versatile human pathogen associated with diverse clinical syndromes, ranging from fulminant sepsis to more persistent subacute infection, 
as often occurs in endocarditis, chronic pneumonia, osteomyelitis 
and in the skin and soft tissues1. While toxins have been shown to 
be critical in the initial stages of pathogenesis2–5, the S. aureus prop-
erties responsible for such indolent infections are not as well estab-
lished. SCVs of S. aureus have long been associated with chronic 
infection6. SCVs often harbour inactivating mutations in genes 
associated with the production of the terminal electron transport 
chain components haeme and menaquinone7. As a result, they 
share major metabolic features including decreased utilization of 
the tricarboxylic acid (TCA) cycle and oxidative phosphorylation 
and upregulation of glycolysis to generate ATP8. They are often 
overlooked in clinical microbiology laboratories due to their slow 
growth and instability in vitro9. While their ability to cause persis-
tent infection has been attributed to antimicrobial resistance, intra-
cellular survival and limited production of toxins necessary to elicit 
immune clearance10, exactly how SCVs are selected in the setting of 
chronic infection is still unclear.
There are important immunological consequences associated 
with microbial induction of host metabolic activity, particularly gly-
colysis11,12. Keratinocytes respond to wild type (WT) S. aureus by 
increasing glycolytic activity and generating HIF1α and IL-1β13. We 
postulated that SCVs activate a metabolic response in host cells, dis-
tinctive from that activated in response to more virulent S. aureus 
strains, which enables them to persist. In this study, we demonstrate 
that by potently activating host glycolysis and mitochondrial reac-
tive oxygen species (ROS), WT S. aureus and a ΔhemB SCV pro-
totype stimulate necroptosis in keratinocytes, a form of cell death 
that eliminates the host cell but releases viable staphylococci14 and 
promotes SCV persistence. Moreover, the ΔhemB SCV upregu-
lates bacterial fumC expression, promoting the degradation of local 
fumarate and inhibiting the generation of trained immunity that 
confers protection against secondary staphylococcal challenge.
Results
Construction and characterization of a ΔhemB mutant in 
USA300 LAC. The phenotypic and metabolic consequences of 
a hemB deletion in the S. aureus 8325-4 background as well as 
mutations in hemB, menD and thyA in numerous clinical isolates 
have previously been characterized8. We used the ΔhemB 8325-4 
mutant as a historical SCV control15 and constructed a hemB dele-
tion mutant and its complement by gene restoration on the chromo-
some in the clinically relevant USA300 LAC background (Extended 
Data Fig. 1a), which were confirmed by whole genome sequenc-
ing (Supplementary Table 1). The use of two SCV prototypes is of 
importance as the historical SCV was constructed in a strain that 
has undergone extensive ultraviolet mutagenesis16 and has defects 
in the activation of the stress response regulator SigB17,18 that could 
impact metabolism. The ΔhemB LAC mutant formed pinpoint 
colonies on BHI agar but exhibited WT-sized, haemolytic colonies 
on blood agar, presumably by scavenging haemin from the media, 
consistent with the loss of δ-aminolevulinic acid dehydratase19 (Fig. 
1a and Extended Data Fig. 1b). The expression of the global regula-
tor agr20 from the ΔhemB LAC mutant was decreased whereas those 
of the genes hla, lukA, lukE, lukS and hlgC encoding α-haemolysin 
(Hla) and subunits of bi-component toxins were all increased, as 
was expression of fnbA, which encodes the fibronectin-binding pro-
tein (Fig. 1b). This is in contrast to the historical ΔhemB mutant 
Staphylococcus aureus small colony variants impair 
host immunity by activating host cell glycolysis 
and inducing necroptosis
Tania Wong Fok Lung   1, Ian R. Monk   2, Karen P. Acker   1, Andre Mu   2,3, Nancy Wang   2, 
Sebastián A. Riquelme1, Silvia Pires   1, Loreani P. Noguera   1, Felix Dach1, Stanislaw J. Gabryszewski1, 
Benjamin P. Howden   2,3,4 and Alice Prince   1*
Staphylococcus aureus small colony variants (SCVs) are frequently associated with chronic infection, yet they lack expression of 
many virulence determinants associated with the pathogenicity of wild-type strains. We found that both wild-type S. aureus and 
a ΔhemB SCV prototype potently activate glycolysis in host cells. Glycolysis and the generation of mitochondrial reactive oxy-
gen species were sufficient to induce necroptosis, a caspase-independent mechanism of host cell death that failed to eradicate 
S. aureus and instead promoted ΔhemB SCV pathogenicity. To support ongoing glycolytic activity, the ΔhemB SCV induced over 
a 100-fold increase in the expression of fumC, which encodes an enzyme that catalyses the degradatin of fumarate, an inhibitor 
of glycolysis. Consistent with fumC-dependent depletion of local fumarate, the ΔhemB SCV failed to elicit trained immunity and 
protection from a secondary infectious challenge in the skin. The reliance of the S. aureus SCV population on glycolysis accounts 
for much of its role in the pathogenesis of S. aureus skin infection.
NATuRe MIcRoBIoLoGy | VOL 5 | JANUArY 2020 | 141–153 | www.nature.com/naturemicrobiology 141
Articles NaTurE MiCrobioloGy
that has reduced hla expression21. However, upregulated expression 
of toxin-encoding genes in the ΔhemB LAC mutant did not result 
in increased protein levels (Fig. 1c). WT LAC and the ΔhemB LAC 
mutant produced similar levels of Hla in the presence of haemin 
(Fig. 1c), consistent with the β-haemolysis observed on blood agar 
(Fig. 1a). The WT and ΔhemB mutant strains also produced simi-
lar levels of LukA during exponential growth phase and the ΔhemB 
mutant made more LukA/D/E than WT LAC in the presence of 
haemin (Fig. 1c), indicating that this SCV is probably capable of 
toxin expression in  vivo. The complemented mutant strain dis-
played a WT phenotype (Fig. 1a–c).
The ΔhemB SCV induces a distinct metabolic response as com-
pared with WT S. aureus. The major property differentiating the 
SCVs as a group and WT S. aureus strains is their altered meta-
bolic activity8. Just as bacteria adapt their metabolic activity in 
specific settings, host cells similarly respond to bacterial infection 
with metabolic changes13,22. We predicted that the ΔhemB mutant 
would induce a distinct metabolic response in comparison to the 
parent strain. A global metabolome analysis of the supernatants 
of infected human peripheral blood mononuclear cells (PBMCs) 
illustrated the different metabolic responses induced by the ΔhemB 
LAC mutant as compared with the WT or complemented strains 
(Fig. 1d). This is shown by the distinct clustering of all metabo-
lites across the different biological groups by partial least-squares 
analysis (Fig. 1d). Major differences in the levels of extracellular 
l-arginine, d-proline, succinate, l-ornithine, adenine and uridine-
5-monophosphate were observed during infection with the SCVs 
versus the WT strain (Fig. 1e).
An analysis of the lower-abundance metabolites revealed less 
fumaric acid, N-acetyl-glutamine, N-acetyl-dl-methionine and 
N-acetyl-l-phenylalanine in the extracellular metabolome of 
ΔhemB SCV-infected PBMCs (Fig. 1f), consistent with the pro-
duction of these metabolites during infection with the WT strain. 
Focusing specifically on the abundance of fumarate, we observed a 
decrease associated with the PBMCs infected with the ΔhemB SCV 
as compared with either the WT or complemented control (Fig. 1g). 
The distinctive metabolome profile including lower levels of fuma-
rate associated with ΔhemB infection was corroborated in a simi-
lar analysis of infected human monocytes (THP-1 cells) (Extended 
Data Fig. 1c–f) and reflects the combined products of both host 
and pathogen metabolism. While all of the S. aureus strains tested 
induced host cell glycolysis, the ΔhemB SCVs stimulated signifi-
cantly more glycolytic activity in THP-1 cells than the WT strain 
(Fig. 1h). This was indicated by a higher extracellular acidification 
rate (ECAR) in Seahorse extracellular flux assays. The overall con-
tribution of bacterial metabolism to the changes in ECAR was neg-
ligible (Fig. 1h), emphasizing the influence of the bacteria on the 
infected host cells. These S. aureus strains also stimulated keratino-
cyte glycolysis (Fig. 1i).
S. aureus stimulates necroptosis by inducing host glycolysis. 
Induction of glycolysis has been linked to the activation of necrop-
tosis23,24. This cell death pathway is mediated by the RIP kinases that 
induce the phosphorylation of MLKL, resulting in oligomerization 
and pore formation25,26. S. aureus can induce necroptotic cell death, 
which has been shown to be toxin-dependent27,28. Necroptosis, in 
contrast to the caspase-1-associated mechanisms of cell death, does 
not kill S. aureus but releases viable organisms14. We observed that 
WT S. aureus and the ΔhemB SCV induced necroptosis in human 
primary keratinocytes, indicated by the phosphorylation of MLKL 
(PMLKL), a response that was inhibited in the presence of a glyco-
lytic inhibitor, 2-deoxyglucose (2-DG; Fig. 2a and Extended Data 
Fig. 2a). Bacterial glycolytic activity was required for the induction 
of host glycolysis13 and necroptosis as neither heat-killed bacteria 
nor a Δpyk mutant (deficient in glycolysis)13,29 that cannot induce 
host glycolysis13 stimulated PMLKL whereas a ΔpckA mutant (defi-
cient in gluconeogenesis13,29) was fully capable of inducing necrop-
tosis (Fig. 2b).
It seemed likely that glycolysis contributes to the induction of 
necroptosis by fuelling the TCA cycle and generating ROS. The 
addition of butylated hydroxyanisole (BHA), a ROS scavenger, and 
an inhibitor of the pyruvate dehydrogenase complex (CPI-613) that 
blocks aerobic respiration and mitochondrial ROS production30 
suppressed the induction of PMLKL (Fig. 2a,c). As the inhibitors of 
glycolysis and ROS could affect both the host and staphylococci, the 
effects of WT and the ΔhemB SCV on host mitochondrial activity 
were determined by measuring mitochondrial membrane potential, 
which remained low as ROS production in the infected cells was 
induced, a response similar to that induced by the positive oxidant 
control, namely tert-butyl hydroperoxide (TBHP)31 (Fig. 2d,e).
To confirm that the metabolic impact of the ΔhemB SCV was 
sufficient to induce necroptosis, we documented that several 
toxin-deficient mutants including Δagr, Δhla and ΔlukAB/ED/SF/
ΔhlgABC activated PMLKL in human keratinocytes (Fig. 2f). 
Moreover, inhibition of the endocytic machinery with cytochalasin 
D had no effect on necroptosis (Fig. 2f). All of the toxin-deficient 
mutants stimulated glycolysis in keratinocytes (Fig. 2g). Thus, there 
appears to be a major impact of S. aureus metabolic activity, inde-
pendent of toxin expression, on the bioenergetics of the host cell, 
sufficient to activate glycolysis, ROS and necroptosis.
S. aureus-induced necroptosis is not dependent on specific 
ligand–receptor interactions or autophagy. Many studies indi-
cate that necroptosis is initiated by tumour necrosis factor recep-
tor 1 (TNFR1) and toll-like receptor (TLR) stimulation, as well as 
Fig. 1 | The S. aureus ScV prototype ΔhemB stimulates a distinct metabolic response in host cells. a, Growth of WT LAC, the ΔhemB LAC mutant and 
the complemented strain, ΔhemB (hemB), on BHI agar and sheep blood agar. Different dilutions of bacterial cultures were plated on each agar plate; the 
image shown is from one representative experiment; n = 3 independent experiments. b, Expression of agr, fnbA, hla, lukA, lukE, lukS and hlgC by qrT–PCr. 
The data represent the mean ± s.e.m.; n = 2 biologically independent experiments in triplicate; rQ, relative quantification to WT LAC. c, A representative 
immunoblot showing the presence or absence of the S. aureus toxins Hla, LukA, LukD and LukE from the supernatants of bacterial cultures grown with or 
without haemin; n = 3 independent experiments. d, representative principal component analysis score plots showing principal component 1 (PC1/variate 
1) versus PC2/variate 2 of the total extracellular PBMC metabolome; n = 1 biological sample in triplicate. e, A heatmap of the total extracellular PBMC 
metabolome; n = 1 biological sample in triplicate. From top to bottom, the arrows indicate metabolites l-arginine, d-proline, succinate, l-ornithine, adenine 
and uridine-5-monophosphate respectively. f, A heatmap of lower-abundance metabolites in the extracellular PBMC metabolome; n = 1 in triplicate. g, 
relative quantification of fumarate in the extracellular metabolome of uninfected and infected PBMCs. The data represent the median with the 95% 
confidence interval; n = 1 biological sample in triplicate. h,i, The ECAr of uninfected (PBS) host cells (human monocytes, THP-1 cells (h), and human 
keratinocytes, HEKn cells (i)), and those infected with WT LAC, ΔhemB LAC and the complemented strain or WT 8325-4 and ΔhemB 8325-4 following 
sequential addition of glucose to stimulate glycolysis, oligomycin to inhibit mitochondrial respiration and shift energy production towards glycolysis, and 
2-DG to inhibit glycolysis. The ECAr of staphylococci at the same concentration was also measured in the absence of host cells. Each data point is the 
mean ± s.e.m.; n = 3 biologically independent experiments. The single asterisks denote statistical differences with respect to the uninfected cells; the double 
asterisks denote differences between the ΔhemB-infected cells and those infected with the WT or complemented strains; P < 0.001 by two-way ANOVA.
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autophagy, since the autophagy machinery serves as a platform for 
the assembly of the necrosome complex32,33. However, these alter-
native pathways were excluded. The ΔhemB SCV induced at least 
as much LC3B production, an autophagy marker, as did the WT 
strain (Fig. 3a). Inhibition of the early stages of autophagy by wort-
mannin (WM) or 3-methyladenine (3-MA) or the late stages with 
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chloroquine (CQ) did not impact the stimulation of PMLKL during 
infection of keratinocytes (Fig. 3a). The TNFR1 and TLR2 pathways 
were also excluded. Short interfering RNA to knockdown Tnfr1 or 
Tlr2 in keratinocytes did not prevent the induction of necroptosis 
(Fig. 3b,c), and TLR2 agonists such as heat-killed S. aureus, lipoara-
binomannan (LAM) or Pam3Cys did not activate PMLKL (Fig. 3d).
ΔhemB SCV-induced necroptosis interferes with bacterial clear-
ance. Given that both WT S. aureus and the ΔhemB SCV induce 
necroptosis, we next examined how this impacts pathogenesis using 
a murine model of skin infection. We hypothesized that induction 
of necroptosis by the ΔhemB SCV would interfere with S. aureus 
clearance from the skin, as this form of host cell death does not kill 
staphylococci14. We compared intracellular survival of WT LAC, the 
ΔhemB LAC mutant and the complemented strain in bone mar-
row-derived macrophages (BMDMs) from WT and Mlkl−/− mice. 
Similar numbers of colony-forming units (CFUs) were obtained at 
1 h post-infection, indicating equivalent bacterial uptake (Fig. 4a). 
All three bacterial strains were cleared in the presence or absence of 
necroptosis at 4 and 24 h post-infection (Fig. 4a), confirming that 
necroptosis does not kill staphylococci. Of note, fewer ΔhemB LAC 





































































































































































































































































































































Fig. 2 | S. aureus stimulates necroptosis via the induction of host glycolysis. a–c, representative immunoblots showing the induction of PMLKL, a marker 
for necroptosis, and PS6, a marker for proliferative activity, in HEKn cells exposed to PBS, WT S. aureus 8325-4, ΔhemB 8325-4 or heat-killed (HK) 
ΔhemB 8325-4 for 4 h in the presence and absence of a glycolytic inhibitor, 2-DG, or a rOS scavenger, BHA (a), or to WT LAC, HK WT LAC, Δpyk LAC 
or ΔpckA LAC for 24 h in the presence and absence of 2-DG (b) or to WT 8325-4 or ΔhemB 8325-4 for 4 h in the presence and absence of an inhibitor 
of the pyruvate dehydrogenase complex, CPI-613 (c). For each immunoblot, n = 3 independent experiments. d, A density plot from a representative 
experiment showing mitochondrial rOS production and membrane potential in HEKn cells exposed to PBS, WT 8325-4, ΔhemB 8325-4 or an inducer 
of mitochondrial rOS, THBP, for 3 h; n = 2 independent experiments in triplicate. e, Mitochondrial rOS production and membrane potential from d. The 
data represent the mean ± s.e.m. n = 2 independent experiments. f, A representative immunoblot showing the induction of PMLKL and PS6 in HEKn cells 
exposed to PBS, WT LAC, Δagr LAC, Δhla LAC or ΔlukAB/ED/SF/ΔhlgABC LAC for 4 h with or without cytochalasin D; n = 2 independent experiments. g, 
The ECAr of uninfected (PBS) HEKn cells and those infected with WT LAC, Δagr LAC, Δhla LAC or ΔlukAB/ED/SF/ΔhlgABC LAC. Each data point is the 
mean ± s.e.m.; n = 3 independent experiments. The single asterisks denote statistical differences with respect to the uninfected cells; the double asterisks 
show statistical differences between the Δhla-infected cells and those infected with the other strains; P < 0.001 by two-way ANOVA. The glycolytic 
activity of the bacteria alone is shown.
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24 h post-infection (Fig. 4b), suggesting that necroptosis promotes 
ΔhemB persistence.
As has been noted by others34,35, primary infection with the 
ΔhemB SCVs was attenuated in  vivo as demonstrated by smaller 
skin lesions (dermonecrosis) and lower bacterial burden in a 
murine model of cutaneous infection (Fig. 4c,d). In spite of the 
decreased bacterial load, the ΔhemB LAC SCVs persisted for at least 
5 days (Fig. 4d) and recruited similar numbers of neutrophils, inter-
stitial macrophages, Ly6C− monocytes, Ly6C+ monocytes, CD11b+ 
dendritic cells (DCs), Langerhans DCs, Langerhans cells and plas-
macytoid DCs (pDCs) (Fig. 4e) but less of the proinflammatory 
cytokines IL-1β, TNFα, IL-6 and KC (Fig. 4f) than did WT LAC at 
the site of infection. Similar results were obtained with the ΔhemB 
8325-4 mutant, which recruited a similar immune response as the 
WT strain except for significantly fewer Langerhans cells (P < 0.01) 
(Extended Data Fig. 2b,c). However, the levels of induction of pro-
inflammatory cytokines by WT 8325-4 and the ΔhemB mutant 
were not statistically different, except for IL-1β and KC (Extended 
Data Fig. 2d).
We next investigated how necroptosis contributes to the host 
response, comparing the clearance of WT LAC and the ΔhemB 
LAC SCV from the skin of Mlkl−/− mice, unable to initiate necrop-
tosis (Fig. 4d and Extended Data Fig. 2b). No statistically significant 
differences were observed in bacterial burdens in the WT C57BL/6 
and Mlkl−/− mice infected with WT LAC (Fig. 4d) or WT 8325-4 
(Extended Data Fig. 2b). However, in contrast to the indolent infec-
tion that persisted in WT C57BL/6 mice, both ΔhemB SCVs failed 
to establish infection in Mlkl−/− mice (Fig. 4d and Extended Data 
Fig. 2b), suggesting that the ability of the host to activate necrop-
tosis is required for the persistent infection caused by the ΔhemB 
SCVs in the skin. No significant differences in immune cell recruit-
ment or cytokine production were observed during infection of WT 
C57BL/6 versus Mlkl−/− mice at five days post-infection (Fig. 4e,f 
and Extended Data Fig. 2c,d).
Compared to the parental strain, the ΔhemB 8325-4 SCV was 
also more readily cleared from the Ripk1d mice, which cannot initi-
ate necroptosis, and evoked a limited innate immune response and 
less IL-1β, TNFα, KC and MIP2 production (Extended Data Fig. 
2b–d). Decreased amounts of proinflammatory cytokines (IL-1β, 
TNF, IL-6 and MIP-2) were induced in the skin of Ripk1d mice com-
pared to WT C57BL/6 mice following infection with the ΔhemB 
8325-4 mutant (Extended Data Fig. 2d). Overall, data obtained with 
ΔhemB mutants in both genetic backgrounds indicate that SCV 
pathogenicity is dependent on the ability of the organisms to acti-
vate necroptosis.
The ΔhemB SCV fails to induce trained immunity. Although the 
ability of SCVs to induce necroptosis contributes to pathogenicity, 
this does not fully explain how the SCVs, which are clearly attenu-
ated in other ways, are so successful in a clinical setting. An impor-
tant consequence of infection with WT S. aureus is the activation 
of local memory in the skin, a response that is conferred by macro-
phages and promotes more effective bacterial clearance following 
secondary exposure36,37. Metabolic changes that result in epigenetic 
reprogramming and increased transcription of proinflammatory 
cytokines following secondary exposure are the hallmark of trained 
immunity in macrophages38. Given the distinct metabolic signature 
observed during ΔhemB SCV infection (Fig. 1d and Extended Data 
Fig. 2c), we postulated that the host metabolic response induced by 
ΔhemB SCVs might limit their ability to elicit trained immunity. 
Skin infection in C57BL/6 mice was initiated by either WT LAC or 
the ΔhemB LAC SCV. Primary infection with WT S. aureus, which 
normally resolves within 15–18 days, elicited protective immunity 
as evidenced by significantly decreased dermonecrosis and CFUs 
when the same site was reinfected 28 days later (Fig. 5a–c). In 
contrast, primary infection with the ΔhemB SCV failed to induce 
protection against a secondary challenge with WT S. aureus; the 






















































































































Fig. 3 | S. aureus-induced necroptosis is independent of autophagy or ligand–receptor interactions. a–d, representative immunoblots showing the 
induction of PMLKL and PS6 in HEKn cells exposed to PBS, WT 8325-4 or ΔhemB 8325-4 and treated with the autophagy inhibitors WM, CQ and 3-MA 
(a), control sirNA or Tnfr1 sirNA (b), control sirNA or Tlr2 sirNA (c) and the TLr2 agonists LAM and Pam3Cys (d). The arrow in b indicates TNFr1. For 
each immunoblot, n = 3 independent experiments.
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Fig. 4 | ΔhemB-induced necroptosis impairs bacterial clearance. a, Intracellular survival of WT LAC, the ΔhemB LAC mutant and the complemented 
strain, ΔhemB (hemB), in WT or Mlkl−/− BMDMs at 1 h, 4 h and 24 h post-infection; n = 2 biologically independent experiments. b, Intracellular bacterial 
survival from a at 24 h post-infection as a percentage of the intracellular survival at 1 h post-infection; n = 2 independent experiments. c–f, Outcomes of 
skin infection in WT C57BL/6 and Mlkl−/− mice 5 days post-infection with WT LAC, ΔhemB LAC or ΔhemB (hemB) LAC. c, Dermonecrosis from days 1–5 
post-infection. d, The bacterial load in WT C57BL/6 and Mlkl−/− mice 5 days post-infection. e, Innate immune cell populations recruited at the site of 
infection at day 5. f, Cytokine measurements from skin biopsies of the infected sites at day 5. For a–f, the data represent the mean ± s.e.m. For c–f, n = 13 
(C57BL/6 WT LAC), 10 (C57BL/6 ΔhemB), 5 (C57BL/6 ΔhemB (hemB)), 10 (Mlkl−/− WT LAC) or 17 (Mlkl−/− ΔhemB) independent animals. Statistical 
analysis was performed by one-way (d–f) and two-way (c) ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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was higher than those from mice that initially encountered WT S. 
aureus (Fig. 5b,c). The participation of T and B cells in the memory 
response to S. aureus infection was examined. Both WT C57BL/6 
and Rag2 knockout (KO) mice exhibited protection against second-
ary infection with smaller lesions although no significant differences 
in CFUs were observed (Fig. 5d,e), findings consistent with recent 
reports36. This indicates that secondary protection against S. aureus 
infection is not solely mediated by adaptive immunity and requires 
trained immunity. Necroptosis was not essential in inducing trained 
immunity; Mlkl−/− mice infected initially with WT S. aureus were 
protected from a secondary challenge with the WT strain (Fig. 5f,g). 
Accordingly, we questioned whether a specific component of the 
metabolic activity of the SCVs inhibits trained immunity.
Increased expression of fumC in the ΔhemB SCV inhibits trained 
immunity. The production of fumarate is important in stimulat-
ing the epigenetic changes associated with trained immunity in 
monocytes39. As a TCA cycle substrate important in oxidative 
phosphorylation, fumarate production would be decreased in cells 
whose metabolic activity is skewed to favour glycolysis, as is the 
case for the SCV-infected cells, particularly since fumarate itself 
suppresses glycolysis40. We predicted that infection with the ΔhemB 
SCV would generate less fumarate, as we observed in  vitro (Fig. 
1g and Extended Data Fig. 1f) and hence would limit the epigen-
etic changes necessary for trained immunity. We established that 
less fumarate accumulates in the supernatant of ΔhemB-infected 
as compared with WT S. aureus-infected keratinocytes (Fig. 6a). 
This was consistent with the upregulation of fumC, which encodes 
fumarate hydratase, an enzyme that converts fumarate to malate 
(Fig. 6b), and correlated with significantly decreased local accumu-
lation of fumarate in infected skin (Fig. 6c). To determine whether 
increased fumC expression in the SCVs would be sufficient to regu-
late local concentrations of fumarate, we performed a mixed infec-
tion in vivo, demonstrating that even with a 1:1 ratio (WT/ΔhemB) 
there was still significantly decreased fumarate accumulation in the 
skin (Fig. 6c). This effect of the ΔhemB SCV was apparent in vivo, 
even though the WT strain significantly outcompeted the ΔhemB 
mutant when infected at either a 1:1 or 1:3 ratio (Fig. 6d,e).
To better appreciate the contribution of increased fumC expres-
sion in pathogenesis, a fumC deletion mutant in the LAC back-
ground was constructed and tested in the murine skin infection 
model, predicting that it would stimulate trained immunity by 
allowing the accumulation of local fumarate. Similar levels of 
fumarate were present in the skin of mice infected with either the 
ΔfumC mutant or WT strain (Fig. 6f). Primary infection with the 
ΔfumC mutant was equivalent to the WT strain as demonstrated by 
similar lesion sizes and bacterial burden (Fig. 6g,h). Mice initially 
infected with either the ΔfumC mutant or WT/complemented 
strains developed local protective immunity following secondary 
challenge with WT S. aureus, as demonstrated by smaller lesions 
and CFUs (Fig. 6i,j). We verified in  vitro that the ΔfumC LAC 
mutant stimulated less glycolysis in keratinocytes than the WT or 
complemented strains, consistent with the anti-glycolytic activity 
of fumarate (Fig. 6k).
A ΔhemBΔfumC double mutant was generated in the LAC back-
ground to enable us to address the importance of upregulated fumC 
expression in the ΔhemB background. We predicted that in the 
absence of fumC, the ΔhemBΔfumC double mutant would no lon-
ger inhibit trained immunity. The ΔhemBΔfumC mutant formed 
pinpoint colonies on BHI agar but WT-sized haemolytic colonies 
on blood agar, as did the ΔhemB mutant (Extended Data Fig. 3a). 
Both the ΔhemB and ΔhemBΔfumC mutants displayed slow growth 
in liquid medium (Extended Data Fig. 3b). Primary infection with 
both mutants was attenuated as demonstrated by decreased der-
monecrosis, bacterial burden and cytokine production compared 
to primary infection with the WT strain (Fig. 6l,m and Extended 
Data Fig. 3c). Although both ΔhemB and ΔhemBΔfumC mutants 
established indolent infections, primary infection with the 
ΔhemBΔfumC mutant elicited protective immunity as evidenced by 
significantly decreased dermonecrosis and bacterial burden when 
the same site was reinfected 28 days later. This protection was simi-
lar to that induced by primary infection with either WT S. aureus or 
the ΔfumC mutant but not the ΔhemB mutant (Fig. 6n,o).
Additional mechanisms that might contribute to the induction 
of local memory by WT but not the SCVs were addressed. The 
production of IL-1β following Aim2 stimulation, which has been 
associated with memory and protective epigenetic changes in the 
skin41, was excluded given that both WT C57BL/6 and Il1r1−/− mice 
lacking IL-1β signalling were protected from secondary challenge 
(Extended Data Fig. 4a,b). Nor were there differences in dermone-
crosis or S. aureus clearance following primary infection of WT 
or Aim2−/− mice (Extended Data Fig. 4c,d). S. aureus also failed to 
activate Aim2 signalling in keratinocytes (Extended Data Fig. 4e,f). 
Thus, our results indicate that the metabolic activities of ΔhemB 
SCVs are biologically significant in inhibiting local fumarate accu-
mulation and enhancing their ability to cause chronic infection.
Discussion
S. aureus SCVs, as modelled by ΔhemB mutants, are an important 
component of the staphylococcal communities associated with 
chronic human infection. Our studies indicate that SCV properties 
unrelated to their more widely recognized antimicrobial resistance 
and intracellular survival play a major role in their pathogenicity. 
The metabolic response induced by SCVs contributes to their suc-
cess as a cause of chronic infection. We demonstrate that WT S. 
aureus and the ΔhemB mutant from both the LAC and 8325-4 back-
Fig. 5 | The ΔhemB ScV fails to induce trained immunity. a–g, WT C57BL/6, Rag2 KO or Mlkl−/− mice were treated with PBS or infected with WT LAC 
or ΔhemB LAC on day 0 and challenged at the same site on day 28 with WT LAC. a, A schematic diagram of in vivo infection. b, Dermonecrosis over the 
course of WT C57BL/6 infection. The black asterisks denote statistical differences in lesion size with respect to uninfected mice, the red asterisks show 
statistical differences between the WT-infected and ΔhemB-infected mice, the purple asterisks show statistical differences between naive and WT-S. 
aureus-primed mice post-secondary challenge and the orange asterisks denote statistical differences between naive and ΔhemB-infected mice; n = 3 
(C57BL/6 PBS PBS), 9 (C57BL/6 PBS WT), 11 (C57BL/6 WT WT) or 16 (C57BL/6 ΔhemB WT) independent mice. c, The bacterial load from b at five days 
post-secondary challenge. d, Dermonecrosis in WT C57BL/6 and Rag2 KO mice treated with PBS or infected with WT LAC on day 0 and challenged at the 
same site on day 28 with WT LAC. The black asterisks denote statistical differences in lesion size with respect to uninfected mice; n = 2 (C57BL/6 or Rag2 
KO PBS PBS), 3 (C57BL/6 PBS WT), 3 (C57BL/6 WT WT), 3 (Rag2 KO PBS WT) or 3 (Rag2 KO WT WT) independent mice. e, The bacterial load from d 
at five days post-secondary challenge. f, Dermonecrosis in Mlkl−/− mice treated with PBS or infected with WT LAC on day 0 and challenged at the same 
site on day 28 with WT LAC. The black asterisks denote statistical differences in lesion size with respect to uninfected mice and the purple asterisks show 
statistical differences between naive and WT-S. aureus-primed mice post-secondary challenge; n = 3 (Mlkl−/− PBS PBS), 5 (Mlkl−/− PBS WT) or 6 (Mlkl−/− 
WT WT) independent mice. g, The bacterial burden from f at five days post-secondary challenge. For b–g, the data represent the mean ± s.e.m. Statistical 
analysis was performed by two-way (b,d,f) and one-way (c,e,g) ANOVA; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; P = 0.1106 (c), P > 0.9999 (e). 
NS, not significant.
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grounds induce glycolysis, which in turn activates host cell necrop-
tosis. While the ΔhemB SCVs are relatively attenuated in their 
ability to cause local skin infection, their induction of necroptosis 
does not eliminate staphylococci but instead promotes their persis-
tence. Although necroptosis has previously been linked to bacterial 
toxin production14,27,28, we found that the variable expression of tox-
ins by the SCVs was not required to induce necroptosis, which was 
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A metabolomic analysis of SCV versus WT S. aureus-infected 
host cells indicated that a specific metabolomic profile is associated 
with SCV infection. SCV upregulation of fumC expression depleted 
local fumarate, both in vitro and in vivo, which correlated with the 
ability of the ΔhemB mutants to evade trained immunity. WT S. 
aureus strains that did not deplete fumarate elicited substantial 
protection from a secondary infectious challenge. In monocytes, 
fumarate is essential for the epigenetic changes associated with 
trained immunity39. Since the ΔhemB SCVs are electron transport 
chain-deficient and dependent on glycolysis, which is inhibited 
by fumarate40, they must actively regulate the abundance of local 
fumarate. Even when SCVs comprised only a fraction of the infect-
ing population of staphylococci, as is likely in a clinical infection, 
their upregulated fumC transcription was sufficient to significantly 
decrease local levels of fumarate. Our data indicate that SCV eva-
sion of trained immunity in the skin did not correlate with the 
intensity of the primary immune response, but instead depended 
on the depletion of local fumarate, adding to the growing body of 
literature demonstrating the importance of metabolites in innate 
immune memory11.
There are major efforts underway to develop S. aureus vaccines 
based on their expression of toxins and surface adhesins. While 
these may be highly effective in blocking infection with virulent 
organisms, the SCVs will remain a challenge. Not only are they 
protected by slow growth, antimicrobial resistance and their often 
intracellular niche, but their metabolic activity also predisposes the 
host to a secondary infection instead of generating protective local 
immunity.
Methods
Bacterial culture. The bacterial strains used in this study are listed in 
Supplementary Table 1. S. aureus USA300 LAC and 8325-4 strains were grown at 
37 °C with shaking in Luria–Bertani broth (LB, BD) and tryptic soy (TS, BD) broth, 
respectively, or on LB, TS or brain heart infusion (BHI, Sigma) supplemented with 
1% agar (Sigma). The ΔhemB 8325-4 mutant was cultured in media supplemented 
with erythromycin 2.5 μg ml−1 (Sigma-Aldrich). The Δpyk LAC strain was 
cultured in media supplemented with sodium pyruvate (Sigma-Aldrich) at a final 
concentration of 5 mg ml−1. Bacterial inocula were estimated on the basis of the 
optical density at 600 nm (OD600nm) and verified by retrospective plating on agar 
plates to determine CFUs. S. aureus recovered from mouse skin biopsies were 
selected on BBL CHROMagar Staph aureus plates (BD).
Primers and plasmids. The primers and plasmids used in this study are listed in 
Supplementary Tables 2 and 3.
Construction of ΔhemB LAC, ΔfumC LAC, ΔhemBΔfumC LAC and 
complemented strains. The hemB and fumC deletion mutants (ΔhemB, ΔfumC) 
in the LAC background were constructed using the pIMAY-Z allelic exchange 
plasmid42. Upstream and downstream products of hemB and fumC were amplified 
from LAC genomic DNA with the primer sets P1/2, P5/6 and P7/8, P9/10, 
respectively. The upstream and downstream products of hemB and fumC were 
joined by splicing by overlap extension PCR with the primers P1/6 and P7/10, 
respectively, gel extracted and cloned by seamless ligation cloning extract43 into 
Escherichia coli IM08B. The plasmids pIMAY-Z∆hemB and pIMAY-Z∆fumC were 
subsequently electroporated into WT LAC and allelic exchange was performed 
as described by Monk et al.42. The LAC ∆hemB and ∆fumC strains were verified 
by PCR and whole genome sequencing. The ∆hemB∆fumC double mutant 
was generated by electroporating pIMAY-Z∆hemB into the ∆fumC strain and 
verified by PCR and whole genome sequencing. Restoration of the hemB and 
fumC genes was achieved by cloning the wild-type hemB and fumC genes with 
the incorporation of a silent restriction enzyme site (SalI or XhoI) by splicing by 
overlap extension PCR into the gene with the primers P1/3/4/6 and P7/12/11/10, 
respectively. The procedure was repeated as described above except the pIMAY-
ZhemB+ and pIMAY-ZfumC+ constructs were transformed into the LAC ∆hemB 
and ∆fumC strains. This yielded the complemented strains LAC ∆hemB (hemB) 
and ∆fumC (fumC).
Isolation of bacterial RNA, complementary DNA synthesis and qRT–
PCR. Triplicate LB cultures of WT LAC, ∆hemB and ∆hemB (hemB) were 
standardized on the basis of OD600 nm. RNAprotect bacteria reagent (QIAGEN) 
was added to bacterial cultures, vortexed and incubated at room temperature 
for 10 min. Bacterial cell pellets were collected by centrifugation, frozen 
and resuspended in 1 ml of TRIsure (Bioline) before lysis by bead beating 
at 6,000 r.p.m. for 40 s (zirconia/silica beads (BioSpec), Precellys tissue 
homogenizer). The debris and beads were pelleted and the supernatants 
were added to equal volumes of 100% ethanol. The sample was processed 
through Direct-zol spin columns (Zymoresearch) with on-column and then 
off-column DNaseI treatment with Turbo DNaseI (Invitrogen), as described 
by the manufacturer. The absence of contaminating DNA was verified by 
PCR with Phire polymerase (Thermo Fisher Scientific) for 35 cycles using 
gyrB primers (P13/14). RNA was converted to cDNA using Superscript IV 
reverse transcriptase (Invitrogen). For qRT–PCR, 1 μl of cDNA was used with 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) using a MX3000P 
QPCR system (Agilent Technologies) with the primer sets P15/16, P17/18, 
P19/20, P21/22, P23/24, P25/26, P27/28 and P13/14 to amplify agrA, fnbA, hla, 
lukA, lukE, lukS, hlgC and gyrB, respectively.
For the measurement of fumC expression, overnight cultures of WT LAC 
and ∆hemB were subinoculated in TS broth supplemented with 0.5% glucose 
and grown statically overnight. The overnight cultures were normalized on the 
basis of OD600 nm and collected by centrifugation. Bacterial pellets were incubated 
in lysis buffer (50 μM Tris-EDTA pH 7.5, 8 U ml−1 mutanolysin (Sigma-Aldrich), 
0.018 mg ml−1 lysostaphin (Sigma-Aldrich), 0.05 mg ml−1 lysozyme (Sigma-
Aldrich)) at 37 °C for 45 min and TRK lysis buffer (Omega Bio-tek) was added. 
After 10 min at room temperature, 70% ethanol was added and samples were 
transferred to E.Z.N.A RNA isolation columns (Omega Bio-tek). RNA was isolated 
Fig. 6 | overexpression of fumC in ΔhemB ScVs inhibits trained immunity. a, Fumarate levels in HEKn media; n = 2 independent experiments. b, 
Expression of S. aureus fumC in WT and ΔhemB LAC by qrT–PCr. n = 3 independent experiments; **P < 0.005, by Mann–Whitney U-test. c, Fumarate in 
murine skin infected with WT S. aureus (n = 5 independent samples), ΔhemB (n = 7) or a mixed inoculum at a 1/1 ratio (n = 7). d, The competitive index of 
ΔhemB versus WT S. aureus in skin infected with WT to ΔhemB ratios of 1/1 (n = 7) and 1/3 (n = 3). A competitive index of 1 indicates equal colonization 
capabilities to the parental strain. e, Dermonecrosis in C57BL/6 mice infected with WT S. aureus (n = 5), ΔhemB (n = 7) or mixed inocula at ratios of 
1/1 (n = 7) and 1/3 (n = 3). The black asterisks denote statistical differences with respect to uninfected mice; the coloured asterisks denote comparison 
with WT S. aureus single infection. f, Fumarate in murine skin infected with WT LAC, ΔfumC LAC or the complemented strain; n = 5. g, Dermonecrosis at 
five days post-infection with the strains in f. The black and red asterisks denote statistical differences in lesion size with respect to uninfected mice and 
between WT and ΔfumC (fumC)-infected mice, respectively; n = 5. h, The bacterial load from g on day 5. i, Dermonecrosis in WT mice treated with PBS, 
WT LAC, ΔfumC LAC or the complemented strain on day 0 and challenged at the same site on day 28 with WT LAC; the black, red and orange asterisks 
denote statistical differences in lesion size with respect to uninfected mice, WT and ΔfumC-infected mice, and between naive and primed mice post-
secondary challenge, respectively; n = 5 or 6. j, The bacterial load from i at five days post-secondary challenge. k, The ECAr of uninfected (PBS) and WT 
LAC-, ΔfumC LAC- or complemented strain-infected HEKn cells. The single asterisks show comparisons to uninfected cells; the double asterisks compare 
ΔfumC-infected to WT-infected cells, n = 3. l, Dermonecrosis at five days post-infection with WT LAC, ΔhemB or ΔhemBΔfumC LAC. The black asterisks 
denote statistical differences in lesion size between WT-infected and uninfected mice; the blue and cyan asterisks denote statistical differences in lesion 
size between WT-infected and ΔhemB-infected mice, and between WT-infected and ΔhemBΔfumC-infected mice, respectively; n = 4 or 5. m, The bacterial 
load from l on day 5. n, Dermonecrosis in mice treated with PBS, WT LAC, or the ΔhemB, ΔhemBΔfumC or ΔfumC LAC mutants on day 0 and challenged 
at the same site on day 28 with WT LAC. The black, orange and blue asterisks denote statistical differences in lesion size with respect to uninfected mice, 
between naive or ΔhemB-primed mice; or between WT LAC and ΔhemBΔfumC or ΔfumC-primed mice post-secondary challenge; n = 4 or 5 independent 
mice per group. o, The bacterial load from n at day 5. For a–o, the data represent the mean ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 
one-way (c,f,h,j,m,o) or two-way ANOVA (e,g,i,k,l,n); P = 0.9074, 0.8807 (WT versus ΔfumC or ΔfumC (fumC), respectively), 0.9999 (ΔfumC versus 
ΔfumC (fumC) (f); P = 0.2210 (o). NS, not significant.
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following the manufacturer’s instructions and treated with DNase using the DNA-
free DNA removal kit (Invitrogen). Mutltiscribe reverse transcriptase (Applied 
Biosystems) was used to generate cDNA for qRT–PCRs with Power SYBR Green 
PCR Mastermix (Applied Biosystems). qRT–PCR was performed using primers 
for fumC and 16S (P29/30, P31/32) and a StepOne Plus thermal cycler (Applied 
Biosystems), and data were analysed using the ∆∆CT method.
Exoprotein isolation from S. aureus. Overnight S. aureus cultures were 
subcultured for 6.5 h with (10 μM) or without haemin (Sigma) and standardized 
at an OD600 nm of 8. Bacterial cells were pelleted by centrifugation at 4,000 r.p.m. for 
10 min. The supernatants were filtered through a 0.2-µm-pore-size filter (Nalgene) 
and precipitated with 10% (v/v) trichloroacetic acid (Sigma) at 4 °C overnight. The 
precipitated proteins were washed with 100% ethanol, air-dried, resuspended with 
8 M urea (Sigma) and 2 × LDS loading buffer (Life Technologies) and boiled.
Host cell culture. Human primary keratinocytes (HEKn, Gibco, C0015C) were 
cultured in DermaLife basal medium (Lifeline Cell Technology) supplemented 
with growth factors (DermaLife K LifeFactors kit, Lifeline Cell Technology), 
1% fetal bovine serum (FBS, Gibco) and 1% penicillin/streptomycin (Pen/Strep, 
Corning) and used up to passage 8. THP-1 cells (ATCC, TIB-202) were cultured 
in RPMI 1640 medium containing l-glutamine (Corning) and supplemented with 
10% FBS and 1% Pen/Strep and differentiated with phorbol 12-myristate 13-acetate 
(PMA, Sigma-Aldrich) at a final concentration of 1 μM for 48 h. The HEKn and 
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cultured in DMEM (Corning) supplemented with 1% FBS with or without Pen/
Strep. All cell lines were routinely tested for mycoplasma contamination.
Infection of human primary keratinocytes and THP-1 cells. HEKn cells were 
seeded at 2 × 105 cells ml−1 in 24-well plates 24 h before infection and bacterial 
strains were cultured in liquid broth overnight. On the day of infection, all 
bacterial cultures were subinoculated 1:100 in liquid culture, except for the ΔhemB 
strains, and grown to an OD600 nm of 1. Fibronectin (Corning) was added to HEKn 
cells at 10 μg ml−1 1 h before infection along with 2-DG (Sigma-Aldrich), BHA 
(Sigma-Aldrich), a pyruvate dehydrogenase inhibitor (CPI−613, Selleckchem), 
cytochalasin D (Sigma-Aldrich) and the autophagy inhibitors WM (Calbiochem), 
3-MA (Sigma-Aldrich) and CQ (Sigma) at final concentrations of 100 mM, 
200 μM, 300 μM, 20 μM, 5 μM, 20 μM and 50 μM, respectively. The TLR2 agonists 
Pam3Cys (Invivogen) and lipoarabinomannan (Invivogen) were added at a final 
concentration of 10 μg ml−1 1 h before infection for a total of 5 h. Heat-killed S. 
aureus was prepared by treating bacteria at 65 °C for 1 h. HEKn cells were infected 
with the various S. aureus strains at a multiplicity of infection (m.o.i.) of 50 for 
4 or 24 h. For 24 h infections, lysostaphin was added 4 h post-infection at a final 
concentration of 10 μg ml−1.
Transfection of human primary keratinocytes. Human Tlr2 and Tnfr1 siRNAs 
(Dharmacon) and non-targeting control siRNAs (Santa Cruz) were reverse-
transfected for 24 h into HEKn cells using Lipofectamine RNAiMAX (Life 
Technologies) according to the manufacturer’s instructions. Keratinocytes were 
transfected with poly dA:dT (InvivoGen) at a final concentration of 1 μg ml−1 using 
Lipofectamine 3000 (Life Technologies) as per the manufacturer’s protocol.
RNA extraction from mammalian cells. RNA was extracted from human 
keratinocytes using the E.Z.N.A Total RNA kit (Omega Bio-tek), followed by 
DNase treatment and reverse transcription as described above. The primer pairs 
P33/34 and P35/36 were used to amplify the genes coding for Aim2 and actin.
Lysostaphin protection assay. BMDMs were isolated from mice, differentiated in 
the presence of 20 ng ml−1 of murine M-CSF (Peprotech) and seeded at 1.15 × 106 
cells ml−1 in DMEM (Corning) supplemented with 1% FBS. BMDMs were infected 
at an m.o.i. of 50 for 30 min and washed. Fresh DMEM containing 1% FBS and 
10 μg ml−1 lysostaphin (Sigma) was then added until the desired time point. The 
cells were washed, detached using TrypLE Express (Life Technologies), serially 
diluted and plated on BHI agar. Cell viability was determined by counting live cells 
using the trypan blue (Life Technologies) exclusion method44.
Extracellular flux analysis. HEKn cells were seeded at 30,000 cells per well in 
a Seahorse XF24 well plate (Agilent Technologies) and incubated at 37 °C with 
5% CO2. A sensor cartridge was calibrated as per the manufacturer’s instructions 
overnight at 37 °C without CO2. On the day of infection, the primary keratinocytes 
were washed once in XF base medium (Agilent) supplemented with 2 mM 
glutamine, and fibronectin was added at 10 μg ml−1 1 h before infection. The 
cells were infected at an m.o.i. of 50 and incubated at 37 °C without CO2 for 3 h. 
The ECAR was measured using an XF24 analyser (Seahorse Bioscience). Each 
measurement cycle consisted of a mixing time of 3 min and a data acquisition 
period of 3 min (12 data points). Glucose was added at a final concentration of 
10 mM to stimulate glycolysis followed by the addition of oligomycin at 1 μM 
to suppress oxidative phosphorylation and 2-DG at 50 mM to inhibit glycolysis. 
Whenever THP-1 cells were used, they were seeded at a density of 150,000 cells 
per well and differentiated with PMA. The metabolic activity of the bacteria was 
determined by adding the same amount of bacteria in XF24 well plates without 
HEKn cells.
Metabolomics analysis. Human PBMCs were isolated from whole blood using 
Vacutainer CPT tubes (BD) according to the manufacturer’s instructions. Following 
hypotonic lysis of red blood cells, the cells were seeded at a density of 1 × 106 
cells ml−1 in XF base medium (Agilent) supplemented with 2 mM l-glutamine for 
3 h. Glucose was then added at a final concentration of 10 mM for 30 min. Tissue 
culture supernatants were then saved for metabolite extraction. A 50% methanol 
solution (v/v) was used to extract metabolites from tissue culture supernatants. 
High-resolution mass spectrometry data were acquired on the Exactive Mass 
Spectrometer (Thermo Fisher) in negative mode using 25 min reverse phase 
gradients and ion-pairing chromatography at the University of Calgary. Metabolites 
were identified using the known chromatographic retention times of standards, and 
metabolite signals were quantified using MAVEN45. The extracellular metabolites 
detected from PBMCs are listed in Supplementary Table 4.
THP-1 cells were seeded at a density of 3 × 106 cells per well in a 6-well tray 
and differentiated with PMA 48 h before infection. On the day of infection, the 
cells were washed once and infected at an m.o.i. of 50 in XF base medium (Agilent) 
supplemented with 2 mM l-glutamine for 3 h. Glucose was then added at a final 
concentration of 10 mM for 30 min. Tissue culture supernatants were then saved 
for metabolite extraction and the cells were washed once in Milli-Q water before 
lysis using liquid nitrogen. A methanol/chloroform solution (9:1 v/v) containing 
0.5 nM 13C-sorbitol and 5 nM 13C,15N-valine as internal standards was used to 
extract metabolites from cell lysates, and tissue culture supernatants. Samples 
were processed at Metabolomics Australia (Bio21, The University of Melbourne, 
Australia) on a gas chromatography–triple-quadrupole mass spectrometer. 
Metabolite detection was performed using the Smart Metabolites Database 
(Shimadzu). The Automatic Adjustment of Retention in GCMSsolution software 
(version 4.42 Shimadzu) and a standard alkane series mixture (C7-C33, Restek) 
were used to correct retention time shifts in the acquisition method. Annotated 
metabolites were quantified. To determine the relationship between samples, 
partial least-squares discriminant analysis46 was computed using the mixOmics R 
package47. Multivariate analysis plots were generated using the R function plotIndiv 
(Plot Of Individuals), with the ellipses representing 95% confidence intervals of the 
sample space. The relative abundance of each metabolite was log-transformed and 
the median of all metabolites from each sample was then calculated. Metabolites 
from each sample were then normalized to the median to account for any 
biomass variability and plotted as a heatmap using GraphPad Prism Version 7.00 
(GraphPad). The intracellular and extracellular metabolites from THP-1 cells are 
listed in Supplementary Tables 5 and 6, respectively.
Western blotting. Proteins isolated from bacterial cultures were separated by gel 
electrophoresis, transferred to PVDF membranes (Invitrogen) and probed with 
anti-Hla (Sigma), anti-LukA, anti-LukE and anti-LukD (gift from V. J. Torres) at 
concentrations of 1:5,000, 1:5,000, 1:10,000 and 1:7,500, respectively.
HEKn cells were lysed in RIPA lysis buffer (1 mM Tris-HCl, pH 7.5, 15 mM 
NaCl, 0.5 mM EDTA, 0.01% SDS, 0.1% Triton X-100, 0.1% deoxycholate) 
containing 1× HALT protease inhibitor cocktail (ThermoFisher Scientific). 
Protein concentrations were quantified using the Precision Red advanced protein 
kit (Cytoskeleton) and samples were standardized to a concentration of 100 μg. 
The samples were subjected to gel electrophoresis and the gels (Invitrogen) 
were transferred to PVDF membranes (Invitrogen) using the iBlot machine 
(LifeTechnologies). Antibodies against PMLKL, MLKL, PS6, TNFR1 (Cell 
Signaling), TLR2 (EMD Millipore) and LC3B, β-actin (Sigma-Aldrich) were used 
according to the manufacturer’s instructions. Secondary antibodies conjugated to 
horseradish peroxidase (Abcam, Santa Cruz) were diluted 1:10,000. Images were 
visualized using a digital chemiluminescent detection imager (ProteinSimple) 
and ImageJ.
Mitochondrial ROS and membrane potential measurement. HEKn cells 
were infected at an m.o.i. of 50 for 3 h. Cells were stimulated with TBHP (Life 
Technologies) at a final concentration of 400 μM for 1 h. The cells were washed, 
detached with TrypLE Express (Life Technologies) and stained for mitochondrial 
membrane potential (Dilc1(5), Invitrogen), cell viability (LIVE/DEAD stain, 
Invitrogen) and mitochondrial ROS (MitoSox, Invitrogen) for 20 min at 37 °C in 
DermaLife medium. The cells were washed three times with PBS and analysed 
using a FACS CantoII flow cytometer machine.
Mice. Male and female mice were purchased from Jackson Laboratories (C57BL/6; 
stock number 000664, Il1r1−/−; stock number 003245, Aim2−/−; stock number 
029472, Rag2 KO; stock number 008449). Mlkl−/− mice14,48 were obtained from J. 
Silke (WEHI Australia) via D. R. Green (St Jude Children’s Research Hospital) and 
Ripk1d (Ripk1K45A) mice49,50 were obtained from S. B. Berger from GlaxoSmithKline. 
The animal work protocol (AAAR5412) was approved by the Institutional 
Animal Care and Use Committee. Animal experiments were carried out in strict 
accordance with the recommendations in the Guide for the Care and Use of 
Laboratory Animals of the NIH, the Animal Welfare Act, and US federal law. Mice 
were aged 6–8 weeks at the start of the experiment.
Mouse infection. Mice were infected intradermally on the back with 1 × 107 CFUs 
of S. aureus 8325-4 or the isogenic ΔhemB mutant in 100 μl PBS or 2 × 106 CFUs 
of S. aureus USA300 LAC or the ΔhemB, ΔhemBΔfumC or ΔfumC mutants or 
the complemented strains in 100 μl PBS. PBS alone was used as a control. For 
trained immunity experiments, mice were challenged with the WT strain 28 days 
following primary infection at the same site. Lesions were measured and punch 
biopsies (5 mm) were taken in the middle of the infected lesion. The biopsied tissue 
was homogenized through 40 μm cell strainers (Falcon) before the hypotonic lysis 
of red blood cells. The homogenates were serially diluted and plated. Bacterial 
counts were enumerated. Keratinocytes and immune cells were spun down at 700g 
at 4 °C and the supernatants were used for cytokine analysis. Immune cells were 
stained with fluorescently conjugated markers and analysed by flow cytometry. No 
calculation was used to determine the number of mice required. No data blinding 
was performed.
Flow cytometry measurement. Human keratinocytes were stained with LIVE/
DEAD stain (Invitrogen) for 20 min at 4 °C, washed and permeabilized with 
permeabilization buffer (0.05% saponin, 2% FBS in PBS) for 10 min at room 
temperature. The cells were then stained with anti-Aim2 antibody (Abcam) for 
30 min at 4 °C, washed and stained with secondary antibodies before fixing with 
2% paraformaldehyde (Electron Microscopy Sciences).
Red blood cells were lysed from mouse skin homogenates and the 
remaining cells were washed with FACS buffer (10% FBS and 0.1% sodium 
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azide in PBS). Cells were stained for 30 min at 4 °C in the presence of counting 
beads (Bangs Laboratories) and labelled with a combination of BV605-
labelled anti-CD11c (Biolegend), BV421-lalbelled CD86 (Biolegend), BV510-
labelled CD103 (Biolegend), PE–CF594-labelled anti-Ly6C (BD Horizon), 
PerCP–Cy5.5-labelled anti-Ly6G (Biolegend), BV650-labelled anti-NK-1.1 
(Biolegend), AF700-labelled CD45 (Biolegend), APC/Cy7-labelled MHCII 
(Biolegend), PE-labelled CD207 (Biolegend), AF594-labelled anti-CD11b 
(BioLegend) and Fc block (Biolegend). Analysis of immune cell populations 
was conducted using BD LSR II (BD Biosciences). Cells in the skin were 
classified as follows: Langerhans cells, CD45+CD11b+CD11c+MHCII+CD207+; 
Langerhans DCs, CD45+CD11b+CD11c+MHCII+CD207+CD103
+; interstitial macrophages, CD45+Ly6C−CD11b+CD11c+MHCII+; 
Ly6C− monocytes, CD45+Ly6C−CD11b+CD11c+MHCII−; CD11b+ DCs, 
CD45+Ly6C+CD11b+MHCII+CD11c+; neutrophils (polymorphonuclear 
neutrophils), CD45+Ly6C+CD11b+MHCII−Ly6G+; Ly6C+ monocytes, 
CD45+Ly6C+CD11b+MHCII−Ly6G−; pDCs, CD45+Ly6C+CD11b−CD11c+MHCII+. 
All flow cytometry data were analysed on FlowJo version 10.
Cytokine analysis. Supernatants from in vivo tissue homogenates were collected 
and cytokine concentrations were quantified by Eve Technologies (Calgary, 
Canada).
Quantification of fumarate. Fumarate quantification was performed using the 
fumarate assay kit (Abcam) according to the manufacturer’s instructions.
Statistical analysis. Samples without a normal distribution were analysed using 
the non-parametric Mann–Whitney test. Samples with normal distribution were 
analysed using one- or two-way analysis of variance (ANOVA). P < 0.05 between 
groups was considered significant. Statistical analysis was performed using 
GraphPad Prism Version 7.00 (GraphPad).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Whole genome sequence data of the ΔhemB, ΔfumC and ΔhemBΔfumC LAC 
mutants and the complemented strains ΔhemB (hemB) and ΔfumC (fumC) 
were submitted to the European Nucleotide Archive under BioProject number 
PRJEB30093, accession numbers ERS3011129, ERS3011131, ERS3398722, 
ERS3011130 and ERS3011132, respectively. Data that support the findings of this 
study are available from the corresponding author upon request.
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Extended data 1 | ΔhemB LAc ScVs stimulate a distinct metabolic response in THP-1 cells. (A) Construction of the ΔhemB mutant in the USA300 LAC 
background. (B) White light image of WT LAC and the ΔhemB LAC mutant on BHI and blood agar plates to better illustrate pinpoint size of the ΔhemB 
LAC mutant on BHI agar and β (complete)-hemolysis on blood agar, image shown is from 1 representative experiment, n = 3 independent experiments. 
(c) representative PCA score plots showing principal component 1 (PC1/variate 1) versus PC2/variate 2 of the total intracellular and extracellular 
THP-1 metabolomes, n = 2 independent experiments in triplicate. (D) Heatmaps of the total intracellular and extracellular THP-1 metabolomes, n = 2. 
(e) Heatmap of lower abundance metabolites in the extracellular THP-1 metabolomes, n = 2. (F) relative quantification of fumarate in the extracellular 
metabolome of uninfected and infected THP-1 cells. Data represent median with 95% CI, n = 2 independent experiments in triplicate..
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Extended data 2 | Necroptosis promotes ΔhemB ScV persistence. (A) A representative immunoblot showing the induction of PMLKL and PS6 in 
HEKn cells exposed to PBS, WT LAC, ΔhemB LAC or the complemented strain for 4 h in the presence and absence of 2-DG or BHA, n = 3 independent 
experiments. (B) Bacterial load in skin biopsies 5 days following infection of WT C57BL/6 or Ripk1d or Mlkl−/− mice with WT 8325-4 and ΔhemB 8325-4. 
(c) Innate immune cell recruitment from (B) at day 5. (D) Cytokine measurements from mouse skin biopsies from (B) at day 5 For (B-D), data represent 
mean ± SEM, n = 15 (C57BL/6 WT), n = 17 (C57BL/6 ΔhemB). n = 15 (Ripk1d WT), n = 12 (Ripk1d ΔhemB), n = 9 (Mlkl−/− WT) or n = 10 (Mlkl−/− ΔhemB) 
independent animals. Statistical analysis was performed by one-way ANOVA, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05..
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Extended data 3 | characterization of the ΔhemBΔfumC double mutant. (A) Growth of the ΔhemBΔfumC double mutant as compared to WT LAC, the 
ΔhemB or ΔfumC single mutants on BHI and blood agar plates. Various dilutions of bacterial cultures were plated. Image shown is from 1 representative 
experiment, n = 3 independent experiments. (B) Growth of the ΔhemBΔfumC double mutant as compared to WT LAC and the ΔhemB single mutant 
in liquid LB culture. n = 3 independent experiments. (c) Cytokine measurements from the skin of mice 5 days post infection with WT LAC or the 
ΔhemBΔfumC mutant. Data represent mean ± SEM, n = 4 independent animal samples.. Statistical analysis was performed by one-way ANOVA, ****p < 
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05..
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Extended data 4 | Protection against secondary S. aureus infection is independent of IL1R1-Aim2 activation. (A-B) (A) Dermonecrosis and (B) bacterial 
load in WT C57BL/6 and Il1r1−/− mice treated with PBS or infected with WT LAC on day 0 and challenged at the same site on day 28 with WT LAC; black 
asterisks denote statistical differences in lesion size with respect to uninfected mice, purple asterisks show statistical difference between WT C57BL/6 
and Il1r1−/−-infected mice and green asterisks show statistical differences between WT C57BL/6 and Il1r1−/−-naïve mice upon secondary challenge, n = 
2 (C57BL/6 or Il1r1−/− PBS PBS), n = 5 (C57BL/6 PBS WT or C57BL/6 WT WT), n = 4 (Il1r1−/− PBS WT) or n = 6 (Il1r1−/− WT WT) independent animals. 
(c-D) (c) Dermonecrosis and (D) bacterial load in the skin of WT C57BL/6 and Aim2−/− mice 5 days post infection with WT LAC, ns: not significant, 
n = 3 or 4 independent animals (day 1) or n = 10 independent animals (day 5). (e) Intracellular mean fluorescence intensity (MFI) of Aim2 measured 
by flow cytometry in keratinocytes infected with WT LAC or transfected with poly dA:dT for 24 h, n = 1 representative experiment from 3 independent 
experiments. (F) Expression of Aim2 in HEKn cells infected with WT LAC or transfected with poly dA:dT for 24 h, compared to uninfected cells (PBS) by 
qrT-PCr, n = 1 representative experiment from 3 independent experiments, For (A-F), data represent mean ± SEM. Statistical analysis was performed by 
one-way (B) or two-way ANOVA (A, c and D), ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns; p = 0.9999 (c, day 1), 0.9051 (c, day 2), 0.6533 
(c, day 3), 0.9820 (c, day 4), 0.9899 (c, day 5) and p = 0.0892 (D, day 1) and 0.4037 (D, day 5).
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Software and code
Policy information about availability of computer code
Data collection No software used. 
Data analysis We used FlowJo version 10 and GraphPad Prism version 7 to analyse the data in this study. 
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Data that support the findings of this study are included in this manuscript along with the supplementary figures and are also available from the corresponding 
author upon request. Whole genome sequence data of the ΔhemB, ΔfumC and ΔhemBΔfumC LAC mutants and the complemented strains ΔhemB (hemB) and 
ΔfumC (fumC) were submitted to European Nucleotide Archive (ENA) under BioProject number PRJEB30093. 
2






Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
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Sample size Sample sizes were large enough to detect the effects of interest holding biological significance. 
Data exclusions No data were excluded. 
Replication The experimental findings were reliably reproduced. Please see details in the figure legends.
Randomization Samples and animals were randomly allocated into experimental groups.
Blinding No blinding was performed.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
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Antibodies used Rabbit anti-phospho-MLKL Cell Signaling Technology Cat# 91689 
Rabbit anti-MLKL Cell Signaling Technology  Cat# 14993 
Rabbit anti-phospho-S6 ribosomal protein Cell Signaling Technology Cat# 4858 
Rabbit anti-LC3B Sigma-Aldrich Cat# L7543 
Rabbit anti-TLR2 EMD Millipore Cat# 06-1119 
Rabbit anti-TNFR1 Cell Signaling Technology Cat# 3736 
Mouse anti-β-actin Sigma-Aldrich  Cat# A5316 
Goat anti-rabbit-HRP Abcam Cat# ab205718 
Mouse IgGκ light chain binding protein-HRP Santa Cruz Cat# sc-516102 
Brilliant Violet 605 hamster anti-mouse CD11c Clone N418 BioLegend Cat# 117333 
Brilliant Violet 421 rat anti-mouse CD86 Clone GL-1 BioLegend Cat# 105031 
Brilliant Violet 510 hamster anti-mouse CD103 Clone 2E7 BioLegend Cat# 121423 
PE-CF594 rat anti-mouse Ly6C Clone AL-21 BD Horizon Cat# 562728 
Alexa Fluor 700 rat anti-mouse CD45 Clone 30-F11 BioLegend Cat# 103128 
APC/Cy7 rat anti-mouse I-A/I-E (MHCII) Clone M5/114.15.2) BioLegend Cat# 107628 
PE mouse anti-mouse/human CD207 (Langerin) Clone 4C7 BioLegend Cat# 144204 
Alexa Fluor 594 rat anti-mouse/human CD11b Clone M1/70 BioLegend Cat# 101254 
Brilliant Violet 650 mouse anti-mouse NK-1.1 Clone PK136 BioLegend Cat# 108735 
PerCP/Cy5.5 rat anti-mouse Ly6G Clone 1A8 BioLegend Cat# 127616 
Rat anti-mouse CD16/32 (Fc block) Clone 93 BioLegend Cat# 101302 
Rabbit anti-Aim2 Abcam Cat# ab180665 
Rabbit anti-LukA, anti-LukE, anti-LukD (gift from Dr. Victor J. Torres, NYU) 
Rabbit anti-Hla Sigma-Aldrich Cat# S7531
Validation All antibodies were validated for specific use and the relevant literature was listed on the manufacturers' website.
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Policy information about cell lines
Cell line source(s) Human epidermal keratinocytes (HEKn) Gibco Cat# C0015C 
Human monocytes (THP-1) ATCC Cat# TIB-202 
Authentication All cell lines used were authenticated by the manufacturers and checked morphologically under the microscope. 
Mycoplasma contamination All cell lines used were routinely tested for mycoplasma contamination and were mycoplasma free. 
Commonly misidentified lines
(See ICLAC register)
No commonly misidentified cell lines were used. 
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals C57BL/6 Jackson Laboratory Stock No. 000664 
Il1r1-/- Jackson Laboratory Stock No. 003245 
Aim2-/- Jackson Laboratory Stock No. 029472 
Rag2 KO Jackson Laboratory Stock No. 008449 
Mlkl-/- from John Silke, WEHI Australia, via Douglas R. Green, St Jude Children’s Research Hospital (Murphy et al., 2013, Kitur et 
al., 2016) 
Ripk1d (Ripk1K45A) from Scott B. Berger, Peter J. Gough, GlaxoSmithKline (Berger et al., 2014) 
 
Wild animals This study did not involve wild animals. 
Field-collected samples This study did not involve samples collected from the field. 
Ethics oversight Animal work protocol (AAAR5412) was approved by the Institutional Animal Care and Use Committee (IACUC). Animal 
experiments were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory 
Animals of the NIH, the Animal Welfare Act, and US federal law. 
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All plots are contour plots with outliers or pseudocolor plots.
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Methodology
Sample preparation Please see the Methods section. 
Instrument BD LSR II (BD Biosciences) and BD FACS CantoII (BD Biosciences)
Software FlowJo version 10
Cell population abundance No flow activated cell sorting was performed in this study. 
Gating strategy Please see the Methods section. 
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
